The groundbreaking rise of Sildenafil presented a considerable chance for shareholders , but its exclusivity has expired , creating a complex landscape. Off-brand versions have flooded the space , cutting into revenues and putting a strain on profit percentages . While established healthcare companies hold a stake in this field , the potential look